Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EDIT Editas Medicine Inc
- Stocks
- Healthcare
- NASDAQ: EDIT
Price (delayed)
$2.345
Market cap
$196.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.04
Enterprise value
$143.33M
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a
Highlights
The debt has soared by 151% YoY but it has contracted by 7% from the previous quarter
The revenue has declined by 48% year-on-year but it has grown by 11% since the previous quarter
EDIT's equity has dropped by 79% year-on-year and by 54% since the previous quarter
Editas Medicine's net income has shrunk by 51% YoY and by 6% QoQ
Key stats
What are the main financial stats of EDIT
Market
Valuations
Earnings
Shares outstanding
83.71M
Market cap
$196.31M
Enterprise value
$143.33M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.12
Price to sales (P/S)
5.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4
Revenue
$35.84M
Gross profit
$35.84M
Operating income
-$260.33M
Net income
-$251.23M
EBIT
-$260.76M
EBITDA
-$254.44M
Free cash flow
-$215.28M
Per share
Balance sheet
Liquidity
EPS
-$3.04
EPS diluted
-$3.04
Free cash flow per share
-$2.59
Book value per share
$0.75
Revenue per share
$0.43
TBVPS
$3.17
Total assets
$263.65M
Total liabilities
$201.23M
Debt
$85.71M
Equity
$62.42M
Working capital
$151.73M
Debt to equity
1.37
Current ratio
3.08
Quick ratio
3.03
Net debt/EBITDA
0.21
Margins
Efficiency
Dividend
EBITDA margin
-710%
Gross margin
100%
Net margin
-701.1%
Operating margin
-726.4%
Return on assets
-76.3%
Return on equity
-166.3%
Return on invested capital
-123.4%
Return on capital employed
-136.9%
Return on sales
-727.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EDIT stock price
How has the Editas Medicine stock price performed over time
Intraday
9.58%
1 week
15.52%
1 month
55.3%
1 year
-53.47%
YTD
84.65%
QTD
102.16%
Financial performance
How have Editas Medicine's revenue and profit performed over time
Revenue
$35.84M
Gross profit
$35.84M
Operating income
-$260.33M
Net income
-$251.23M
Gross margin
100%
Net margin
-701.1%
The net margin has plunged by 193% YoY but it has grown by 4.4% from the previous quarter
EDIT's operating margin has dropped by 172% year-on-year but it is up by 7% since the previous quarter
Editas Medicine's net income has shrunk by 51% YoY and by 6% QoQ
The revenue has declined by 48% year-on-year but it has grown by 11% since the previous quarter
Price vs fundamentals
How does EDIT's price correlate with its fundamentals
Growth
What is Editas Medicine's growth rate over time
Valuation
What is Editas Medicine stock price valuation
P/E
N/A
P/B
3.12
P/S
5.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4
EDIT's EPS is down by 46% year-on-year and by 6% since the previous quarter
EDIT's P/B is 103% above its last 4 quarters average of 1.4 but 5% below its 5-year quarterly average of 3.0
EDIT's equity has dropped by 79% year-on-year and by 54% since the previous quarter
The P/S is 84% less than the 5-year quarterly average of 31.5 but 21% more than the last 4 quarters average of 4.1
The revenue has declined by 48% year-on-year but it has grown by 11% since the previous quarter
Efficiency
How efficient is Editas Medicine business performance
EDIT's return on sales has dropped by 173% year-on-year but it is up by 6% since the previous quarter
EDIT's return on invested capital has dropped by 132% year-on-year and by 29% since the previous quarter
Editas Medicine's ROA has plunged by 128% YoY and by 20% from the previous quarter
The ROE has decreased by 47% from the previous quarter
Dividends
What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EDIT.
Financial health
How did Editas Medicine financials performed over time
EDIT's total assets is 31% higher than its total liabilities
EDIT's total assets is down by 40% YoY and by 23% QoQ
EDIT's total liabilities is up by 38% year-on-year but it is down by 2.9% since the previous quarter
The debt is 37% more than the equity
The debt has soared by 151% YoY but it has contracted by 7% from the previous quarter
The company's debt to equity has surged by 99% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.